合并快速型心律失常的危重患者静脉应用胺碘酮的研究

Study on intravenous amiodarone in critically ill patients with tachycardiac arrhythmia

目的评价合并快速型心律失常的危重患者静脉应用胺碘酮的疗效及安全性。方法选择合并快速型心律失常的危重患者72例,其中61例伴有不同程度的心力衰竭。患者均静脉应用胺碘酮,并给予胺碘酮口服治疗。将心律失常转复为窦性心律或心率明显减慢评价为显效;心律失常未纠正但心率减慢评为有效;心律失常未纠正且心率未减慢评为无效。密切监测用药前后血压、心率、药物不良反应及心力衰竭情况。结果72例患者中显效率63.89%,有效30.56%,无效率5.55%。大部分患者心力衰竭有不同程度改善,无心力衰竭加重者,未发生严重药物不良反应。结论合并快速型心律失常的危重患者,特别是合并心力衰竭的患者,静脉应用胺碘酮是安全的,疗效是确切的。

Objective To evaluate the efficacy and safety of intravenous amiodarone for critically ill patients with tachycardiac arrhythmia. Methods 72 critically illness with tachycardiac arrhythmia received intravenous amiodarone and oral amiodarone were included in this study. 61 patients were in different degree of heart failure. Blood pressure, heart rate and degree of heart failure were compared before and after intervention. Effects and side effects of intravenous amliodarone were analyzed. Results Clearly effect, effect and no avail rates were 63.89%, 30.56% and 5.55% respectively after intravenous amiodarone. At the same time, the heart failure did not deteriorate after treatment. And no serious side effect was observed during intravenous amiodarone. Conclusions h was efficacy and safety of intravenous amiodarone for critically ill patients with tachyrcardiac arrhythmia, especially for whom with heart failure.